Review of postoperative pharmacological infusions in ischemic skin flaps.
No single drug has yet been found which can overcome the inflammatory and microvascular changes which occur in a skin flap after ischemia-reperfusion. Nevertheless, the continued failure of approximately 7% of all free flap transfers clinically suggests that there may be a place for pharmacological intervention at the time of threatened flap failure. To date, plastic and reconstructive microsurgeons have been reluctant to use drugs because of the mass of conflicting evidence emanating from the plastic surgery literature. However, scientists and surgeons now have a clearer understanding of the problems arising in ischemia-reperfusion. Multi-acting drugs which can inhibit most of the important inflammatory changes would be the ideal. This review considers some of the historical developments in the pharmacological treatment of ischemic flaps in the past decade and looks to the future when pharmacological infusions may be part of the routine for salvaging failing skin flaps.
Knight
K R
KR
Department of Chemical Pathology, St. Vincent's Hospital, Melbourne, Victoria, Australia.
D000255:Adenosine Triphosphate / Q000627:therapeutic use; D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use; D004338:Drug Combinations; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D016166:Free Radical Scavengers / Q000627:therapeutic use; D006801:Humans; D007261:Infusions, Intra-Arterial; D011453:Prostaglandins / Q000627:therapeutic use; D015427:Reperfusion Injury / Q000188:drug therapy*; D016879:Salvage Therapy; D013524:Surgical Flaps; D014665:Vasodilator Agents / Q000627:therapeutic use
D000925:Anticoagulants; D004338:Drug Combinations; D005343:Fibrinolytic Agents; D016166:Free Radical Scavengers; D011453:Prostaglandins; D014665:Vasodilator Agents; D000255:Adenosine Triphosphate